Vir Biotechnology logo

Vir Biotechnology

VIR | NASDAQ
Chart Builder DCF Calculator
$9.58
-$0.38 (-3.82%)
At close: Nov 16, 2026, 4:00 PM ET
$9.59
+$0.01 (+0.10%)
After-hours: Nov 16, 2026, 7:55 PM ET
-3.82%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
45.8
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #376/1021 (Top 37%)

Key Statistics

Market Data

Market Cap $1.64B
1D Range
9.57 10.04
52W Range
5.44 13.65

Valuation (TTM)

PE -7.60
PB 1.83
EV/EBITDA -6.55

Valuation (NTM)

Forward PE N/A
Forward PEG 0.12
Price Target $23.50
Loading financial charts...

Profile

Vir Biotechnology, Inc. operates as an immunology company with commercialized products, dedicated to devising therapeutic solutions for the treatment and prevention of significant infectious diseases....

Sector Healthcare
Industry Biotechnology
Employees 367
IPO Date Oct 11, 2019
Website www.vir.bio
Fiscal Year January - December

Latest News

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

4 days ago · businesswire.com

Vir Biotechnology Announces Pricing of Public Offering of Common Stock
Vir Biotechnology Announces Proposed Public Offering

4 days ago · businesswire.com

Vir Biotechnology Announces Proposed Public Offering
Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48

6 days ago · marketbeat.com

Vir Biotechnology Hepatitis Delta Treatment Meets Phase III Goals, With 79% Virus-Free at Week 48
Vir Biotechnology: Fairly Valued After Phase 3 Success?

6 days ago · seekingalpha.com

Vir Biotechnology: Fairly Valued After Phase 3 Success?
Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript

8 days ago · seekingalpha.com

Vir Biotechnology, Inc. (VIR) Discusses ECLIPSE 1 Topline Results and Expanded SOLSTICE Data Transcript
Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment

8 days ago · investors.com

Vir, A Gilead Rival, Shoots To Two-Year High On Its 'Clean Win' In Hepatitis D Treatment
Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know

8 days ago · zacks.com

Wall Street Analysts Predict a 75.59% Upside in Vir Biotechnology (VIR): Here's What You Should Know
Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data

8 days ago · gurufocus.com

Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta

8 days ago · gurufocus.com

Vir Biotechnology Announces Primary Endpoint Met in Pivotal Phase 3 ECLIPSE 1 Trial for Elebsiran and Tobevibart in Chronic Hepatitis Delta
What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call

12 days ago · marketbeat.com

What Vir Biotechnology (VIR) Said on Its Q3 Earnings Call

Earnings

Latest Earnings
Nov 4, 2026
EPS
-$0.57
Beat +26.01%
REV
-$188K
Miss -116.44%
Next Earnings
Feb 22, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$23.50
Upside
+145.30%
Buy (6)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.